Risk for Dementia Similar With SGLT2 Inhibitors, Dulaglutide in T2DM
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 26, 2024 -- For older adults with type 2 diabetes, the risk for dementia seems similar with sodium-glucose cotransporter 2 (SGLT2) inhibitors and the glucagon-like peptide 1 receptor agonist (GLP-1 RA) dulaglutide, according to a study published online Aug. 27 in the Annals of Internal Medicine.
Bin Hong, from the School of Pharmacy at Sungkyunkwan University in Suwon, South Korea, and colleagues compared the risk for dementia between SGLT2 inhibitors and dulaglutide in a target trial emulation study using nationwide health care data for South Korea obtained between 2010 and 2022. Participants were aged 60 years or older with type 2 diabetes and were initiating treatment with SGLT2 inhibitors (12,489 patients; 51.9 percent dapagliflozin and 48.1 percent empagliflozin) or dulaglutide (1,075 patients).
The researchers found that during a median follow-up of 4.4 years, the primary outcome event of presumed clinical onset of dementia occurred in 69 and 43 participants in the SGLT2 and dulaglutide groups, respectively, with an estimated risk difference of −0.91 percentage points (95 percent confidence interval, −2.45 to 0.63) and estimated risk ratio of 0.81 (95 percent confidence interval, 0.56 to 1.16).
"In conclusion, we found little difference in the risk for dementia for SGLT2 inhibitors compared with dulaglutide in our data," the authors write. "However, whether these findings generalize to newer GLP-1 RAs is uncertain."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Greater Neighborhood Disadvantage Tied to Inflammatory, Alzheimer Disease Biomarkers
THURSDAY, July 3, 2025 -- Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older...
Lower Risk of Alzheimer Disease Seen for Breast Cancer Survivors
MONDAY, June 30, 2025 -- Breast cancer survivors have a lower risk of Alzheimer disease (AD) compared with cancer-free controls, according to a study published online June 20 in...
Late-Life Mood Disorders May Indicate Predisposition to Dementia
MONDAY, June 30, 2025 -- Alzheimer disease (AD) and diverse non-AD tau pathologies may contribute to late-life mood disorders (LLMDs), according to a study published online June 9...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.